Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor-Specific Mutant Peptide–MHC Complex (Neoantigen)
- Molecular classification
- Peptide-MHC Complex, Antigen
01
Overview
A tumor-specific mutant peptide–MHC complex, or neoantigen, is a molecular structure formed when peptides derived from tumor-specific mutations are presented on the surface of cancer cells by MHC molecules. These neoantigens are not present in normal tissues and arise due to somatic mutations unique to the tumor, making them highly specific targets for immune recognition and cancer immunotherapy.
- Other names
- NeoantigenTumor-specific neoantigenMutant peptide–MHC complex
02
Mechanism of action
Neoantigen-based therapies prime or redirect T cells to specifically target and kill tumor cells expressing the unique neoantigen.
03
Biological functions
Antigen presentationT-cell activationImmune responseTumor rejection
04
Disease associations
Cancer
05
Safety considerations
Off-target effects (though less likely than with tumor-associated antigens)Limited to patients whose tumors express immunogenic neoantigensPotential for immune-related adverse events (irAEs)Tumor escape mechanisms (e.g., downregulation of MHC)
06
Interacting drugs
Personalized cancer vaccines
1 more in the full profile.
07
Biomarkers
Neoantigen expressionT-cell reactivity to neoantigenMHC binding affinity of neoantigen peptidesNeoantigen clonality
Beyond the preview
Go deeper on Tumor-Specific Mutant Peptide–MHC Complex (Neoantigen).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tumor-Specific Mutant Peptide–MHC Complex (Neoantigen).